A chemogenetic approach for temporal and cell-specific activation of endogenous GPCRs in vivo.

Cell-specific regulation of endogenous G protein-coupled receptors (GPCRs) is crucial for understanding their roles in physiological processes. We present chemogenetic tools using shield-1-dependent irreversible protein switches to regulate peptide agonist activity. To demonstrate this platform, we engineered chemogenetically regulated pituitary adenylate cyclase activating polypeptide (cPACAP), which exhibited >15-fold chemical-dependent regulation of endogenous receptor activity. In vivo application of cPACAP allowed neuronal activation via the endogenous receptor for PACAP, engaging neural circuits that control respiratory and feeding behaviors. By integrating cPACAP with transgenic mice, we selectively activated endogenous PACAP receptor signaling in hypocretin-expressing neurons of the lateral hypothalamic area (LHA), revealing its role in regulating sighing, a stress-related physiological output. We further extended this design to chemogenetically regulate the parathyroid hormone receptor and corticotropin-releasing factor peptide receptor activity. Using a common small molecule, these chemogenetic tools enable temporally regulated peptidergic activation of endogenous GPCRs in targeted cell populations, facilitating the study of their function.

• Publication year

  2026

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2026-01-09

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1073/pnas.2501228123PMID 41512025PMCID PMC12799120
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphorylation of pyruvate dehydrogenase inversely associates with neuronal activity.

  2024cited by this paper
• DART.2: bidirectional synaptic pharmacology with thousandfold cellular specificity

  2024cited by this paper
• Fast and slow: Recording neuromodulator dynamics across both transient and chronic time scales

  2024cited by this paper
• Unlocking opioid neuropeptide dynamics with genetically encoded biosensors

  2024cited by this paper
• PACAP and VIP Neuropeptides’ and Receptors’ Effects on Appetite, Satiety and Metabolism

  2023cited by this paper
• PACAP Controls Endocrine and Behavioral Stress Responses via Separate Brain Circuits

  2023cited by this paper
• Molecular insights into peptide agonist engagement with the PTH receptor.

  2023cited by this paper
• Understanding VPAC receptor family peptide binding and selectivity

  2022cited by this paper
• Subcellular location defines GPCR signal transduction

  2022cited by this paper
• A general method for chemogenetic control of peptide function

  2022cited by this paper
• PACAP orchestration of stress-related responses in neural circuits.

  2021cited by this paper
• In vivo photopharmacology with a caged mu opioid receptor agonist drives rapid changes in behavior

  2021cited by this paper
• Chimeric GPCRs mimic distinct signaling pathways and modulate microglia responses

  2021cited by this paper
• A single–cell type transcriptomics map of human tissues

  2021cited by this paper
• Cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors

  2021cited by this paper
• Discovery of Selective Pituitary Adenylate Cyclase 1 Receptor (PAC1R) Antagonist Peptides Potent in a Maxadilan/PACAP38-Induced Increase in Blood Flow Pharmacodynamic Model.

  2021cited by this paper
• Brain Circuit of Claustrophobia-like Behavior in Mice Identified by Upstream Tracing of Sighing.

  2020cited by this paper
• Targeting the PAC1 Receptor for Neurological and Metabolic Disorders

  2019cited by this paper
• The amidated PACAP1-23 fragment is a potent reduced-size neuroprotective agent.

  2019cited by this paper
• Genetically Targeted Optical Control of an Endogenous G Protein-Coupled Receptor.

  2019cited by this paper
• Light-activated chimeric GPCRs: limitations and opportunities.

  2019cited by this paper
• Subcellular Organization of GPCR Signaling.

  2018cited by this paper
• Discovery of PACAP and its receptors in the brain

  2018cited by this paper
• PARALLEL CIRCUITS FROM THE BED NUCLEI OF STRIA TERMINALIS TO THE LATERAL HYPOTHALAMUS DRIVE OPPOSING EMOTIONAL STATES

  2018cited by this paper
• The Molecular Basis of G Protein-Coupled Receptor Activation.

  2018cited by this paper
• Functional selectivity of GPCR-directed drug action through location bias

  2017cited by this paper
• Chemogenetic Interrogation of a Brain-wide Fear Memory Network in Mice.

  2017cited by this paper
• A light- and calcium-gated transcription factor for imaging and manipulating activated neurons

  2017cited by this paper
• Deconstructing behavioral neuropharmacology with cellular specificity

  2017cited by this paper
• Sighing.

  2017cited by this paper
• The peptidergic control circuit for sighing

  2016cited by this paper
• Impact of PACAP and PAC1 receptor deficiency on the neurochemical and behavioral effects of acute and chronic restraint stress in male C57BL/6 mice

  2015cited by this paper
• A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior.

  2015cited by this paper
• Orthogonal Optical Control of a G Protein-Coupled Receptor with a SNAP-Tethered Photochromic Ligand

  2015cited by this paper
• A PKA activity sensor for quantitative analysis of endogenous GPCR signaling via 2-photon FRET-FLIM imaging

  2014cited by this paper
• Chemogenetic Inactivation of Ventral Hippocampal Glutamatergic Neurons Disrupts Consolidation of Contextual Fear Memory

  2014cited by this paper
• Chemogenetic tools to interrogate brain functions.

  2014cited by this paper
• Ultra-sensitive fluorescent proteins for imaging neuronal activity

  2013cited by this paper
• Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor

  2011cited by this paper
• Substitution of 5-HT1A Receptor Signaling by a Light-activated G Protein-coupled Receptor*

  2010cited by this paper
• Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder.

  2010cited by this paper
• Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior.

  2009cited by this paper
• Temporally precise in vivo control of intracellular signalling

  2009cited by this paper
• Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms?

  2009cited by this paper
• VPAC and PAC receptors: From ligands to function.

  2009cited by this paper
• HaloTag: a novel protein labeling technology for cell imaging and protein analysis.

  2008cited by this paper
• Biological and Structural Analysis of Truncated Analogs of PACAP27

  2008cited by this paper
• Novel genetically encoded biosensors using firefly luciferase.

  2008cited by this paper
• Neurotrophic effects of PACAP in the cerebellar cortex.

  2007cited by this paper
• Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand

  2007cited by this paper
• [Neuropeptide PACAP and neuropsychological function: unexpected insights from mouse mutants].

  2007cited by this paper
• Physiological roles of G protein-coupled receptor kinases and arrestins.

  2007cited by this paper
• Genome-wide atlas of gene expression in the adult mouse brain

  2007cited by this paper
• Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).

  2005cited by this paper
• In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity.

  2004cited by this paper
• Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.

  2004cited by this paper
• A general method for the covalent labeling of fusion proteins with small molecules in vivo

  2003cited by this paper
• Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis

  2001cited by this paper
• Prohormone Convertases 1 and 2 Process ProPACAP and Generate Matured, Bioactive PACAP38 and PACAP27 in Transfected Rat Pituitary GH4C1 Cells

  1999cited by this paper
• Controlling signaling with a specifically designed Gi-coupled receptor.

  1998cited by this paper
• Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.

  1998cited by this paper
• Distribution of the mRNA for a pituitary adenylate cyclase‐activating polypeptide receptor in the rat brain: An in situ hybridization study

  1996cited by this paper
• Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.

  1992cited by this paper
• Allele-specific activation of genetically engineered receptors.

  1991cited by this paper
• Role of mu 1-opiate receptors in supraspinal opiate analgesia: a microinjection study.

  1988cited by this paper
• 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.

  1987cited by this paper

• No citing papers are available for this paper.